Axsome Short Long Term Debt vs Common Stock Analysis

AXSM Stock

USD 71.71 0.19 0.27%

Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Short Long Term Debt and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Short Long Term Debt vs Common Stock

Short Long Term Debt vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Short Long Term Debt account and Common Stock. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Axsome Therapeutics' Short Long Term Debt and Common Stock is -0.47. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Common Stock in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Short Long Term Debt and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Axsome Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Short Long Term Debt i.e., Axsome Therapeutics' Short Long Term Debt and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.47

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Long Term Debt

The total of a company’s short-term and long-term borrowings.

Common Stock

Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 27th of April 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.

Axsome Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total
Total Assets		0.83	0.86	0.86	0.71	-0.8	-0.74	0.81	0.87	0.87	0.42	0.48	0.86	0.87	0.85	0.89	-0.19	0.51	0.43	0.41	0.59	0.84	0.79	0.55	0.82	0.84
Short Long Term Debt Total	0.83		0.98	0.98	0.5	-0.77	-0.97	0.95	0.93	0.93	0.59	0.68	0.94	0.96	1.0	0.96	-0.36	0.67	0.54	0.23	0.78	0.92	0.86	0.02	1.0	1.0
Other Current Liab	0.86	0.98		0.99	0.63	-0.72	-0.94	0.95	0.89	0.89	0.51	0.61	0.96	0.99	1.0	0.94	-0.32	0.61	0.48	0.15	0.7	0.96	0.92	0.12	0.98	0.99
Total Current Liabilities	0.86	0.98	0.99		0.57	-0.77	-0.96	0.98	0.92	0.92	0.58	0.68	0.94	0.99	0.99	0.96	-0.32	0.68	0.53	0.23	0.77	0.97	0.93	0.11	0.98	0.99
Total Stockholder Equity	0.71	0.5	0.63	0.57		-0.2	-0.34	0.45	0.36	0.36	-0.21	-0.12	0.66	0.69	0.56	0.44	0.03	-0.08	-0.1	-0.24	-0.05	0.67	0.64	0.66	0.5	0.56
Net Debt	-0.8	-0.77	-0.72	-0.77	-0.2		0.78	-0.8	-0.95	-0.95	-0.75	-0.76	-0.69	-0.69	-0.76	-0.91	0.33	-0.78	-0.67	-0.79	-0.89	-0.66	-0.62	-0.13	-0.77	-0.75
Retained Earnings	-0.74	-0.97	-0.94	-0.96	-0.34	0.78		-0.98	-0.92	-0.92	-0.73	-0.82	-0.86	-0.92	-0.96	-0.94	0.41	-0.8	-0.62	-0.29	-0.88	-0.91	-0.88	0.12	-0.97	-0.95
Accounts Payable	0.81	0.95	0.95	0.98	0.45	-0.8	-0.98		0.92	0.92	0.69	0.78	0.86	0.95	0.96	0.94	-0.42	0.77	0.6	0.32	0.85	0.96	0.94	0.02	0.96	0.94
Cash	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92		1.0	0.7	0.76	0.86	0.87	0.93	0.99	-0.36	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Cash And Short Term Investments	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92	1.0		0.7	0.76	0.86	0.87	0.93	0.99	-0.36	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Common Stock Total Equity	0.42	0.59	0.51	0.58	-0.21	-0.75	-0.73	0.69	0.7	0.7		0.96	0.45	0.47	0.56	0.65	-0.45	0.99	0.86	0.61	0.9	0.49	0.5	-0.27	0.58	0.53
Common Stock Shares Outstanding	0.48	0.68	0.61	0.68	-0.12	-0.76	-0.82	0.78	0.76	0.76	0.96		0.52	0.58	0.66	0.72	-0.38	0.97	0.74	0.54	0.93	0.61	0.61	-0.26	0.68	0.64
Other Current Assets	0.86	0.94	0.96	0.94	0.66	-0.69	-0.86	0.86	0.86	0.86	0.45	0.52		0.95	0.95	0.91	-0.28	0.55	0.53	0.13	0.61	0.88	0.81	0.2	0.94	0.96
Other Stockholder Equity	0.87	0.96	0.99	0.99	0.69	-0.69	-0.92	0.95	0.87	0.87	0.47	0.58	0.95		0.98	0.91	-0.3	0.58	0.44	0.12	0.66	0.98	0.94	0.18	0.96	0.98
Total Liab	0.85	1.0	1.0	0.99	0.56	-0.76	-0.96	0.96	0.93	0.93	0.56	0.66	0.95	0.98		0.96	-0.33	0.66	0.52	0.21	0.76	0.95	0.9	0.08	1.0	1.0
Total Current Assets	0.89	0.96	0.94	0.96	0.44	-0.91	-0.94	0.94	0.99	0.99	0.65	0.72	0.91	0.91	0.96		-0.34	0.73	0.61	0.47	0.85	0.87	0.81	0.11	0.96	0.96
Short Term Debt	-0.19	-0.36	-0.32	-0.32	0.03	0.33	0.41	-0.42	-0.36	-0.36	-0.45	-0.38	-0.28	-0.3	-0.33	-0.34		-0.46	-0.51	-0.22	-0.45	-0.34	-0.35	0.23	-0.36	-0.33
Common Stock	0.51	0.67	0.61	0.68	-0.08	-0.78	-0.8	0.77	0.77	0.77	0.99	0.97	0.55	0.58	0.66	0.73	-0.46		0.85	0.57	0.92	0.6	0.61	-0.21	0.67	0.63
Other Liab	0.43	0.54	0.48	0.53	-0.1	-0.67	-0.62	0.6	0.64	0.64	0.86	0.74	0.53	0.44	0.52	0.61	-0.51	0.85		0.53	0.76	0.44	0.43	-0.14	0.53	0.5
Net Tangible Assets	0.41	0.23	0.15	0.23	-0.24	-0.79	-0.29	0.32	0.56	0.56	0.61	0.54	0.13	0.12	0.21	0.47	-0.22	0.57	0.53		0.65	0.12	0.12	0.11	0.23	0.2
Current Deferred Revenue	0.59	0.78	0.7	0.77	-0.05	-0.89	-0.88	0.85	0.89	0.89	0.9	0.93	0.61	0.66	0.76	0.85	-0.45	0.92	0.76	0.65		0.67	0.65	-0.25	0.78	0.74
Non Current Assets Total	0.84	0.92	0.96	0.97	0.67	-0.66	-0.91	0.96	0.83	0.83	0.49	0.61	0.88	0.98	0.95	0.87	-0.34	0.6	0.44	0.12	0.67		0.99	0.18	0.93	0.93
Non Currrent Assets Other	0.79	0.86	0.92	0.93	0.64	-0.62	-0.88	0.94	0.78	0.78	0.5	0.61	0.81	0.94	0.9	0.81	-0.35	0.61	0.43	0.12	0.65	0.99		0.17	0.87	0.87
Other Assets	0.55	0.02	0.12	0.11	0.66	-0.13	0.12	0.02	0.09	0.09	-0.27	-0.26	0.2	0.18	0.08	0.11	0.23	-0.21	-0.14	0.11	-0.25	0.18	0.17		0.01	0.06
Long Term Debt	0.82	1.0	0.98	0.98	0.5	-0.77	-0.97	0.96	0.93	0.93	0.58	0.68	0.94	0.96	1.0	0.96	-0.36	0.67	0.53	0.23	0.78	0.93	0.87	0.01		1.0
Non Current Liabilities Total	0.84	1.0	0.99	0.99	0.56	-0.75	-0.95	0.94	0.92	0.92	0.53	0.64	0.96	0.98	1.0	0.96	-0.33	0.63	0.5	0.2	0.74	0.93	0.87	0.06	1.0

Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.5M	186.1M	(338.4M)	331.5M	588.2M	617.6M
Short Long Term Debt Total	19.9M	50.1M	49.7M	94.7M	186.4M	195.7M
Other Current Liab	683.2K	8.7M	9.3M	57.5M	96.9M	101.8M
Total Current Liabilities	24.5M	23.4M	23.1M	96.6M	138.9M	145.8M
Total Stockholder Equity	(175.9M)	(278.8M)	(409.2M)	109.6M	191.0M	200.5M
Net Debt	(200.0M)	(133.8M)	(36.8M)	(106.2M)	(199.8M)	(189.8M)
Retained Earnings	(175.9M)	(278.8M)	(409.2M)	(596.3M)	(835.6M)	(793.8M)
Accounts Payable	10.9M	13.5M	13.1M	38.6M	40.7M	42.7M
Cash	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Cash And Short Term Investments	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Common Stock Total Equity	3.0K	3.7K	3.7K	3.8K	4.3K	2.7K
Common Stock Shares Outstanding	34.0M	37.2M	37.6M	40.7M	45.4M	30.1M
Liabilities And Stockholders Equity	(134.1M)	(206.5M)	(338.4M)	331.5M	588.2M	617.6M
Other Current Assets	413.1K	148.4K	45.3K	2.8M	8.1M	8.5M
Other Stockholder Equity	(3.7K)	(3.7K)	(3.8K)	705.9M	1.0B	1.1B
Total Liab	41.8M	72.3M	70.8M	221.9M	397.3M	417.1M
Total Current Assets	220.4M	184.0M	86.5M	245.6M	504.3M	529.5M
Short Term Debt	2.6M	1.2M	620.7K	424.7K	1.3M	1.3M
Common Stock	3.7K	3.7K	3.8K	4.4K	5K	3.2K
Net Tangible Assets	178.7M	113.8M	15.6M	39.6M	45.5M	52.6M
Non Current Assets Total	170.5K	2.1M	1.3M	85.8M	84.0M	88.2M
Non Currrent Assets Other	139.9K	317.4K	322.9K	14.7M	11.0M	11.6M
Other Assets	139.9K	2.1M	(426.1M)	14.7M	13.2M	13.9M
Long Term Debt	17.3M	48.3M	49.1M	94.3M	178.1M	187.0M
Non Current Liabilities Total	17.3M	48.9M	49.1M	125.4M	258.4M	271.3M
Property Plant And Equipment Net	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant And Equipment Gross	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant Equipment	30.6K	52.6K	283.8K	1.1M	1.3M	1.4M
Retained Earnings Total Equity	(107.6M)	(175.9M)	(278.8M)	(409.2M)	(368.3M)	(349.9M)
Long Term Debt Total	3.6M	17.3M	48.3M	49.1M	56.5M	59.3M
Capital Surpluse	108.5M	354.6M	392.6M	424.8M	488.5M	264.6M
Net Invested Capital	198.7M	162.1M	64.7M	203.8M	369.0M	387.5M
Net Working Capital	195.9M	160.6M	63.5M	149.1M	365.4M	383.7M
Capital Stock	3.7K	3.7K	3.8K	4.4K	5K	4.3K

Pair Trading with Axsome Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Axsome Stock

0.86	RZLT	Rezolute Financial Report 9th of May 2024	Pair Corr
0.79	HCWB	HCW Biologics	Pair Corr
0.77	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr
0.73	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.62	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr

The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.

The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:

How To Invest In Axsome

Details

Is Axsome Stock a good investment?

Details

What is Axsome Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Axsome Stock analysis

When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Global Correlations Find global opportunities by holding instruments from different markets
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.27)

Revenue Per Share

5.957

Quarterly Revenue Growth

1.935

Return On Assets

(0.25)

Return On Equity

(1.59)

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axsome Short Long Term Debt vs Common Stock Analysis

Short Long Term Debt vs Common Stock

Short Long Term Debt vs Common Stock Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Common Stock

Axsome Therapeutics fundamental ratios Correlations

Axsome Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axsome Therapeutics fundamental ratios Accounts

Pair Trading with Axsome Therapeutics

Moving against Axsome Stock

Complementary Tools for Axsome Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Short Long Term Debt Total
Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 1.0	Total Liab

Accounts Payable	- 0.98	Retained Earnings
Long Term Debt	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Short Long Term Debt Total
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Non Current Liabilities Total	- 0.95	Retained Earnings